BioCardia (NASDAQ:BCDA) Given “Buy” Rating at HC Wainwright

BioCardia (NASDAQ:BCDA)‘s stock had its “buy” rating restated by equities research analysts at HC Wainwright in a report issued on Monday,Benzinga reports. They presently have a $25.00 target price on the stock.

A number of other brokerages have also commented on BCDA. Wall Street Zen upgraded shares of BioCardia from a “sell” rating to a “hold” rating in a research note on Saturday, August 15th. Zacks Research raised shares of BioCardia from a “strong sell” rating to a “hold” rating in a report on Tuesday, August 11th. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of BioCardia in a research report on Friday, July 17th. One analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $25.00.

BioCardia Stock Down 1.0%

Shares of NASDAQ BCDA traded down $0.01 during midday trading on Monday, hitting $1.00. 126,842 shares of the company’s stock were exchanged, compared to its average volume of 1,272,767. The firm has a market capitalization of $15.14 million, a PE ratio of -1.56 and a beta of 0.48. BioCardia has a 12 month low of $0.75 and a 12 month high of $2.29. The company’s 50 day moving average price is $0.96 and its 200 day moving average price is $1.07.

BioCardia (NASDAQ:BCDA) last announced its quarterly earnings results on Wednesday, August 12th. The company reported ($0.13) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.18) by $0.05. On average, equities research analysts anticipate that BioCardia will post -0.71 EPS for the current year.

Insiders Place Their Bets

In related news, Director Simon H. Stertzer acquired 70,200 shares of the stock in a transaction dated Monday, June 22nd. The stock was purchased at an average cost of $0.92 per share, with a total value of $64,584.00. Following the completion of the purchase, the director directly owned 127,338 shares in the company, valued at $117,150.96. This trade represents a 122.86% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Over the last quarter, insiders have bought 140,700 shares of company stock valued at $131,966. 17.40% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On BioCardia

Several institutional investors have recently bought and sold shares of BCDA. Cetera Investment Advisers bought a new position in shares of BioCardia during the second quarter valued at about $40,000. Geode Capital Management LLC grew its position in BioCardia by 70.4% in the 4th quarter. Geode Capital Management LLC now owns 66,003 shares of the company’s stock worth $83,000 after purchasing an additional 27,263 shares in the last quarter. Finally, DRW Securities LLC bought a new stake in BioCardia in the 4th quarter worth about $72,000. Institutional investors own 20.57% of the company’s stock.

About BioCardia

BioCardia, Inc is a clinical-stage biotechnology company dedicated to developing novel cell-based therapies for patients with cardiovascular disease. The company’s core focus lies in advancing regenerative medicine approaches that address both chronic heart failure and acute myocardial infarction. BioCardia leverages proprietary delivery technologies to optimize the targeted administration of therapeutic cells directly into the heart muscle.

The company’s flagship products include the Helix Transendocardial Delivery System and the CardiAMP Cell Therapy System.